磺达肝癸钠治疗高龄急性冠脉综合征的疗效及安全性  

The efficacy and safety of liver decanoic sulfonic sodium in the treatment of elderly patients with acute coronary syndrome

作　　者：陈翔[1] 陀有明 陈少华[1] 苏大理 于斌[1] 李怡新[1] 

机构地区：[1]中山市陈星海医院心内科,广东省中山528415

出　　处：《中国基层医药》2013年第5期673-675,共3页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的观察磺达肝癸钠治疗高龄急性冠脉综合征（ACS）患者的临床疗效及安全性。方法将84例70岁以上高龄ACS患者数字表法随机分成治疗组和对照组，两组均在常规治疗的基础上，治疗组40例加用磺达肝癸钠2．5mg皮下注射，每天1次，疗程8d；对照组44例加用低分子肝素钙0．4ml，2次／d（每12小时1次，根椐体质量调整剂量），脐旁皮下注射，疗程8d，观察两组治疗期间的临床疗效，以及4周时心血管事件和治疗期间出血的发生率。结果治疗组与对照组临床疗效差异无统计学意义（95％比91％，P〉0．05）；两组均未发生死亡、再发心肌梗死及恶性心律失常；两组均未发生大出血，治疗组轻微出血发生率明显低于对照组（7.5％比25％，P〈0．05）。结论磺达肝癸钠与低分子肝素钙治疗ACS均有效，但前者轻微出血的发生率较后者明显降低。磺达肝癸钠用于ACS的抗凝治疗不仅能够有效的减少心血管事件，而且大大降低出血风险，无论患者的年龄、性别、肾功能情况和危险分层，尤其对于出血风险较高的高龄患者更安全，值得临床推广。Objective To observe the efficacy and safety of liver decanoic sulfonic sodium in the treatment of elderly patients with acute coronary syndrome （ACS）. Methods84 ACS patients over 70 years were randomly divided into the treatment and control groups. Two groups were treated on the basis of general, treatment 40 cases of liver of dibutyl sebacate with sodium sulfonated added 2.5 mg subcutaneous injection parumbilical, day 1, course 8 d;control group 44 cases combined with low molecular weight heparin calcium 0.4 ml,2 times/day 1 time every 12 hours, according to body weight adjusted dose, Parumbilical shot in course of 8 days, observing the clinical effect of two groups during the treatment,as well as 4 weeks and bleeding during the treatment the incidence of cardiovascular events. Results The clinical effects of treatment and control groups was no significant difference （95% and 91%, P 〉 0. 05 ） ; None of the two sets of death, myocardial infarction and recurrent malignant ventricular arrhythmia; none of the two sets of bleeding occurs, treatment of minor bleeding rates were significantly lower than those of control groups （7. 5% and 25 % , P 〈 0.05 ）. Conclusion The study of dibutyl sebacate with sodium heparin and low molecular weight heparin calcium in the treatment of ACS are valid, but the former which significantly reduce the incidence of minor bleeding. Liver decanoic sulfonic sodium for acute coronary syndrome ACS）anticoagulation can not only effectively reduce cardiovascular events, but also significantly reduce bleeding risk, regardless of the patient＇s age, gender, renal function and risk stratification,especially for bleeding in high risk elderly patients with safe and clinical promotion.

关 键 词：磺达肝癸钠 低分子肝素钙 急性冠脉综合征 抗凝治疗 

分 类 号：R541.4[医药卫生—心血管疾病]